GE has introduced a third MRI platform in Japan and Europe. The0.5-tesla Vectra system sits in the middle of GE's MRI productline between the Signa--in both its 1.5-tesla and 0.5-tesla versions--andthe MR Max Plus. It was displayed by GE-CGR, GE Medical
GE has introduced a third MRI platform in Japan and Europe. The0.5-tesla Vectra system sits in the middle of GE's MRI productline between the Signa--in both its 1.5-tesla and 0.5-tesla versions--andthe MR Max Plus. It was displayed by GE-CGR, GE Medical Systems'European subsidiary, at the European Congress of Radiology meetingin Vienna last month.
While Vectra widens the number of MRI equipment options GEcan offer its users, the main impetus for its release was to takeadvantage of rapid developments in MRI and computer technology.Vectra offers more advanced fast scanning and image display andprocessing technology than the MR Max at close to an equivalentprice.
"The evolution of electronics and software has providedan opportunity to have a cost-effective product with far betterfeatures than the same cost would have implied four or five yearsago," said Steven C. Riedel, president and CEO of GE-CGR.
Vectra's electronics components are manufactured by GE's YokogawaMedical Systems' subsidiary in Japan, and the magnet is suppliedby GE's U.S. factory, he said.
GE plans its medical product introductions according to theindividual needs of the three major markets in the U.S., Europeand Japan, Riedel said. Vectra meets the strong European demandfor high-end applications at a moderate price.
"We are an early adopter of Vectra. We brought it outas quickly as possible following the Japanese introduction. Thisprovides us with three price/performance points in the line, whichwe can vary with added features," he said.
GE has not, however, ventured into the low-field, permanentmagnet end of the market.
"It is still not clear to us whether there is enough ofa distinction between a 0.5-tesla system and a lower field systemto make it worthwhile to have a 0.2- or 0.3-tesla system in theline. For the moment, we have no offering," Riedel said.
BRIEFLY NOTED:
The two firms will jointly develop version four of DECrad andIDX will develop all future versions. DEC will retain ownershipof related intellectual property. IDX and DEC will jointly displaythe RIS at the Radiological Society of North America conferencein December. The smaller firm will provide service as well asupgrades to DECrad users, although DEC will continue to sell 12-monthDECrad support contracts through June.
DEC's decision to move out of RIS applications developmentconfirms the vendor's focus on building integrated, open computerhealth-care systems compatible with a wide variety of hardwareplatforms and software applications (SCAN 9/11/91). DEC will channelits resources into networking, imaging technologies, multivendorintegration and computing platforms, said Willow Shire, directorof DEC's Healthcare Business Unit.
"IDX will use DECrad to address the radiology department.Digital will use applications like DECrad as building blocks toprovide integrated solutions," Shire said.
"HP's open systems design will be a strategic advantageas interconnectivity and adherence to standards become more importantto customers selecting information systems," said Mark Lamp,ADAC RIS division manager.
The Imlogix 1000 has a 1000 x 1000-pixel display matrix, 12bits deep. The display station is available with image memoryconfigurations of 1000 x 1000-pixel, 2000 x 2000-pixel and 2000x 3000-pixel resolution.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.